The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.

开始日期2026-02-20

申办/合作机构

GALDERMA PHARMA SA

NCT07396168

/ Recruiting临床4期

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.

开始日期2026-02-01

申办/合作机构

The Skin Center Dermatology Group

NCT07352566

/ Not yet recruiting临床4期IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

开始日期2026-01-01

申办/合作机构

The University of California, San Francisco

100 项与尼莫利珠单抗相关的临床结果

登录后查看更多信息

100 项与尼莫利珠单抗相关的转化医学

登录后查看更多信息

100 项与尼莫利珠单抗相关的专利（医药）

登录后查看更多信息

192

项与尼莫利珠单抗相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence

Review

作者: Shanshal, Mohammed ; Uthayakumar, Aarthy

BACKGROUND:

Nemolizumab, an anti-IL-31 receptor A antibody, is licensed for atopic dermatitis and prurigo nodularis; its role in other chronic pruritus (CP) syndromes is uncertain.

OBJECTIVE:

To synthesize efficacy, safety and strength of evidence for nemolizumab in CP beyond these indications. Methods: We conducted a PROSPERO-registered systematic review (CRD420251207054) of databases and trial registries to November 2025 for nemolizumab studies in CP outside AD/PN. Eligible reports were extracted and patients grouped as systemic, neurologic/neurogenic, dermatologic (non-AD) or primary CP/CP of unknown origin.

RESULTS:

Seventeen reports (one randomized trial, two cohorts, 14 case series/reports) describing 114 patients were included. In chronic kidney disease-associated pruritus, a phase II hemodialysis trial showed modest, statistically uncertain benefit versus placebo, contrasting with rapid, near-complete relief in dialysis and cholestatic case reports. Uncontrolled data in neuropathic itch/pain syndromes, non-AD inflammatory and papular dermatoses (notably amyloidosis and perforating disorders) and long-standing primary CP/CPUO described complete itch clearance. Across indications, nemolizumab was well tolerated, but certainty was low for CKD-aP and very low for other groups.

CONCLUSIONS:

Nemolizumab shows plausible antipruritic activity across CP phenotypes, yet the evidence base remains fragile; these signals justify cautious experimental use and prioritize etiology-specific IL-31 receptor blockade trials beyond AD/PN.

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

24-week real world outcomes of nemolizumab in patients with prurigo nodularis

Article

作者: Iozumi, Ken ; Mima, Yoshihito ; Yamamoto, Masako

BACKGROUNDS:

Prurigo nodularis (PN) is a chronic pruritic inflammatory disease associated with immune and neural dysregulation. Although nemolizumab has demonstrated efficacy in clinical trials, real-world post-marketing data remain limited.

OBJECTIVE:

To evaluate the real-world efficacy, safety, and drug survival of nemolizumab in patients with PN.

MATERIALS AND METHODS:

We retrospectively analyzed 38 patients with PN treated with nemolizumab at a single center. Peak Pruritus Numerical Rating Scale (PP-NRS) and Prurigo Nodularis Investigator's Global Assessment (PN-IGA) were assessed up to Week 24. Treatment-emergent adverse events (TEAEs) and drug survival were evaluated.

RESULTS:

Mean PP-NRS rapidly improved from 8.1 at baseline to 1.8 at Week 8 and remained stable through Week 24 (p < 0.001). PN-IGA scores gradually improved from 3.1 to 1.4 by Week 24 (p < 0.01). At Week 24, ≥4-point PP-NRS improvement and PP-NRS 0/1 were achieved in 90.9% and 59.1% of patients, respectively, while PN-IGA 0/1 was achieved in 50.0%. Early PP-NRS improvement correlated with long-term outcomes. TEAEs occurred in 39.5%, mainly cutaneous reactions, and drug survival was significantly lower in patients with TEAEs.

CONCLUSION:

Nemolizumab provided rapid and sustained itch relief with gradual lesion improvement in real-world PN. Early pruritus response may predict long-term efficacy, while adverse events affect treatment persistence.

2026-12-01·MOLECULAR BIOLOGY REPORTS

Construction of genetically modified lactic acid bacteria producing an Anti-Interleukin-31 receptor A Single-chain variable fragment

Article

作者: Murakami, Aito ; Ikeda, Hotaru ; Sato, Takashi ; Namai, Fu ; Yoda, Masahiro ; Shimosato, Takeshi

BACKGROUND:

Nemolizumab, which targets the receptor for interleukin-31 (IL-31R), was approved in Japan in 2022 as a therapeutic antibody agent for atopic dermatitis. IL-31 is a cytokine involved in skin inflammation and pruritus, and recent studies have shown that it is also involved in pulmonary and respiratory diseases. Although antibody therapies such as nemolizumab have proven effective, their drug delivery methods remain suboptimal. Thus, in this study, we attempted to establish a novel local delivery system for IL-31Ra single-chain variable fragment (scFv) using recombinant lactic acid bacteria with the goal of enhancing the value of nemolizumab for future application to respiratory diseases.

METHODS AND RESULTS:

The genetically modified lactic acid bacteria (gmLAB) constructed by electroporation was confirmed by Western blotting to produce recombinant scFv in a nisin-dependent manner. The binding of the recombinant scFv to its target protein, human IL-31Ra, was verified by ELISA. Furthermore, in vitro assay using A549 cells, the purified recombinant scFv was found to significantly inhibit signal transducer and activator of transcription (STAT3) phosphorylation induced by IL-31 stimulation.

CONCLUSIONS:

We successfully constructed a novel tool for expressing IL-31Ra scFv designed based on nemolizumab using gmLAB. The scFv produced by gmLAB specifically bound human IL-31Ra and suggesting that it inhibits IL-31/IL-31Ra signaling. Taken together, our results suggest that the gmLAB established in this study may represent an efficient and convenient new tool for administering IL-31Ra scFv, with potential application to pulmonary and respiratory diseases.

248

项与尼莫利珠单抗相关的新闻（医药）

2026-03-30

·allsci.com

Sanofi’s amlitelimab meets Phase III endpoints in atopic dermatitis with extended 12-week dosing interval

Sanofi (NASDAQ: SNY) reported Phase III data from three trials of amlitelimab in moderate-to-severe atopic dermatitis, showing that the anti-OX40L antibody met primary endpoints across monotherapy and combination settings — with efficacy at a dosing interval of once every 12 weeks that matched the every-four-week regimen. The results, presented as late-breaking research at the 2026 American Academy of Dermatology annual meeting in Denver, position amlitelimab as a mechanistically distinct entrant into a treatment landscape that has grown crowded but remains defined by frequent dosing and incomplete responses. The COAST 1 and COAST 2 trials were randomized, double-blind, placebo-controlled Phase III studies evaluating amlitelimab monotherapy in adults and adolescents aged 12 and older with moderate-to-severe atopic dermatitis. SHORE used the same design but tested amlitelimab in combination with topical corticosteroids, with or without topical calcineurin inhibitors. Across the three trials, 1,786 patients were enrolled at sites spanning North America, Europe, Asia, and Latin America. The primary endpoint for all three studies was the proportion of patients achieving a validated Investigator Global Assessment for atopic dermatitis (vIGA-AD) score of 0 or 1 — clear or almost clear skin — with at least a two-point reduction from baseline at Week 24. Both the Q4W and Q12W amlitelimab arms met this endpoint in each trial.For US and US reference countries, the primary endpoint was vIGA-AD 0/1 with a ≥2-point reduction. Of note, for the EU reference countries and Japan, the studies used co-primary endpoints that included the same vIGA-AD measure plus EASI-75. In COAST 1, vIGA-AD 0/1 rates were 21.1% (Q4W) and 22.5% (Q12W) versus 9.2% for placebo. EASI-75 — the proportion of patients achieving at least 75% improvement in the Eczema Area and Severity Index — reached 35.9% and 39.1% in the Q4W and Q12W arms, respectively, compared to 19.1% for placebo. Itch reduction, measured by a four-point or greater decrease in peak pruritus numerical rating scale, was 22.5% (Q4W) and 24.5% (Q12W) versus 12.7% for placebo. All key secondary endpoints in COAST 1 reached statistical significance. COAST 2 showed a similar pattern, with vIGA-AD 0/1 rates of 25.3% (Q4W) and 25.7% (Q12W) versus 14.8% for placebo. EASI-75 and itch endpoints reached nominal significance, though one secondary endpoint — vIGA-AD 0/1 with barely perceptible erythema — did not achieve statistical significance. The distinction between the two monotherapy trials is worth noting: COAST 2’s higher placebo response rate narrowed the treatment delta, a common challenge in atopic dermatitis trials with geographically diverse enrollment. SHORE, the combination study, produced the highest absolute response rates. vIGA-AD 0/1 was achieved by 28.7% (Q4W) and 32.3% (Q12W) of patients versus 16.8% on placebo plus topical therapy alone. EASI-75 reached 48.1% and 46.8% in the active arms versus 32.3% for placebo. All primary and key secondary endpoints were statistically significant. Across all three trials, Sanofi reported that efficacy was progressively increasing at Week 24 with no evidence of plateau, suggesting that longer treatment durations may yield higher response rates — a pattern that will be tested in the ongoing ESTUARY extension study. The safety profile was consistent with earlier-phase data. The most common adverse events across COAST 1, COAST 2, and SHORE were nasopharyngitis, atopic dermatitis flares, and upper respiratory tract infections, occurring at rates generally comparable to or lower than placebo. Malignancy rates were below 1% and similar between active and placebo groups. No severe injection site reactions or serious gastrointestinal ulceration events were reported. Sanofi disclosed a second case of Kaposi’s sarcoma in the amlitelimab development program, identified in the still-blinded ESTUARY Phase III extension study. Both Kaposi’s sarcoma cases occurred in patients with known risk factors, and both patients discontinued treatment and entered recovery. Out of an estimated 3,778 patients exposed to amlitelimab across all indications, no additional cases have been identified. The signal remains numerically small but warrants monitoring given the immunomodulatory mechanism. Sanofi stated that it “believes that amlitelimab continues to have the potential to be a meaningful and convenient option for patients with AD”. Amlitelimab is a fully human, non-T cell depleting monoclonal antibody that blocks OX40 ligand, a costimulatory molecule involved in the activation and survival of effector T cells. By targeting this upstream pathway, the drug aims to modulate pathogenic immune responses without the broad immunosuppression associated with JAK inhibitors or the cytokine-specific blockade of IL-4/IL-13 antibodies. The non-depleting design distinguishes it from therapies that reduce T cell populations, potentially offering a different safety-efficacy tradeoff. The atopic dermatitis treatment landscape in 2026 includes six approved systemic therapies for moderate-to-severe disease: dupilumab and tralokinumab (both anti-IL-4/IL-13 pathway), lebrikizumab (anti-IL-13), nemolizumab (anti-IL-31 receptor), and the oral JAK1 inhibitors abrocitinib and upadacitinib. All approved injectable biologics require dosing every two to four weeks. Amlitelimab’s Q12W regimen — approximately four injections per year — would represent a substantial reduction in treatment burden if the dosing schedule is maintained in regulatory filings. Cross-trial comparisons are limited by differences in study populations, placebo rates, and endpoint definitions, but the absolute vIGA-AD 0/1 and EASI-75 rates observed in the COAST and SHORE trials are numerically lower than those reported for dupilumab and upadacitinib in their respective pivotal programs. Whether the dosing convenience and mechanistic novelty offset the apparent efficacy gap will be a central question for regulators, payers, and prescribers. Rocatinlimab, developed by Amgen, targets the OX40 receptor rather than the ligand and is also in Phase III development for atopic dermatitis. The two drugs represent competing approaches to the same pathway, and their relative clinical profiles will become clearer as more data emerge. A 2024 review in the Journal of Dermatology and Therapy examined both molecules, noting that while they share a pathway target, their binding sites and downstream effects may differ. Results from ESTUARY, evaluating Q12W maintenance dosing and longer-term safety, are anticipated in the second half of 2026. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

临床结果临床3期免疫疗法

2026-03-28

·Business Wire

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis 1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities 2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis 4,5 ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development, and social confidence. This burden also often extends to caregivers who can experience anxiety, stress, and sleep loss. In our study, nemolizumab demonstrated a clinically meaningful benefit in children with moderate-to-severe atopic dermatitis, helping to reduce skin lesions and itch up to one year, and had a similar safety profile as with adults and adolescents.” LAWRENCE EICHENFIELD, M.D. PROFESSOR OF DERMATOLOGY AND PEDIATRICS AT THE UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE AND CHIEF OF PEDIATRIC DERMATOLOGY AT RADY CHILDREN'S HOSPITAL SAN DIEGO, UNITED STATES Clinically meaningful reductions in skin lesions and itch in children with atopic dermatitis A phase II study (NCT04921345) was conducted to assess the pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis.1 Results showed that nemolizumab pediatric doses were associated with similar pharmacokinetic exposure compared to adults and adolescents, and were well tolerated and effective in children, with clinically meaningful reductions in skin lesions and itch through Week 16 and sustained up to Week 52.1 Amongst two of the cohorts evaluated, children aged 7 to 11 and 2 to 6, with nemolizumab doses of 5 mg (for weights ≥10 kg to <20 kg), 10 mg (for ≥20 kg to <30 kg), and 15 mg (for ≥30 kg): Investigator’s Global Assessment of skin lesion improvement to clear (0) or almost clear (1) skin was observed as early as Week 4, with 41-47% of patients achieving it by Week 16 1 A 75% improvement in the Eczema Area and Severity Index score was observed as early as Week 4, with 69-73% of patients achieving it by Week 16 1 Itch relief - defined as a score of ≥4 on the Peak Pruritus Numerical Rating Scale (PP-NRS) - was observed as early as Week 1, with 72% of children aged 2 to 6 and 59% of children aged 7 to 11 achieving it at Week 16 1 Similar or higher response rates were observed at Week 52 for all these clinical endpoints demonstrating sustained efficacy over a year 1 These phase II findings are consistent with the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis.2,3 “These new data in children below 12 years old build on nemolizumab’s robust and growing clinical evidence base in moderate-to-severe atopic dermatitis. They also demonstrate our commitment to advancing research to address key areas of unmet need in dermatology, such as atopic dermatitis in children, which has such a high prevalence and burden." CHRISTOPHE PIKETTY, M.D., PH.D. GLOBAL PROGRAM HEAD, THERAPEUTIC DERMATOLOGY GALDERMA For adult and adolescent patients with moderate-to-severe atopic dermatitis, nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2,3,9 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and in fibrosis in prurigo nodularis.9-11 It is approved by multiple regulatory authorities around the world for the treatment of adults and adolescent patients with moderate-to-severe atopic dermatitis and adults with prurigo nodularis, including in the U.S. and European Union.2,3 For more information about the impact of atopic dermatitis on children and families, watch this video. Media can find more information and resources on atopic dermatitis in this toolkit. About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com. References Eichenfield LF, et al. Pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis. Late breaking abstract presented at 2026 American Academy of Dermatology (AAD) Annual Meeting; March 27-31, 2026; United States Nemluvio ® U.S. Prescribing Information. Available online . Accessed March 2026 Nemluvio ® European Medicines Agency. Summary of Product Characteristics. Available online . Accessed March 2026 Schoch JJ, et al. Atopic dermatitis: Update on skin-directed management: clinical report. Pediatrics . 2025; 155(6):e2025071812. doi:10.1542/peds.2025-071812 Eichenfield LF, et al. Patient-reported impact of atopic dermatitis on pediatric and adolescent patients with moderate-to-severe disease: results of a real-world, cross-sectional survey. Pediatr Dermatolog y. 2025;42:523-531. doi:10.1111/pde.15940 Vittrup I, et al. The association between atopic dermatitis, cognitive function and school performance in children and young adults. Br J Dermatol . 2023;188(3):341-349. doi: 10.1093/bjd/ljac058 Mostafa N and Smith S D. Improving psychological health outcomes in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2023;16:2821-2827. doi: 10.2147/CCID.S393254 Kelly K A, et al. Skin disease in children: Effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. Children (Basel). 2021;8(11):1057. doi:10.3390/children8111057 Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol . 2020;145(1): 173-182. doi: 10.1016/j.jaci.2019.08.013 Bewley A, et al. Prurigo nodularis: A review of IL-31RA blockade and other potential treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555- 022-00782-2 Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunology . 2022;11(5):e1390. doi: 10.1002/cti2.1390

临床结果临床2期上市批准

2026-03-28

·医学界皮肤频道

成人中重度AD系统治疗指南更新｜2026 AAD

*仅供医学专业人士阅读参考医学界2026 AAD现场直击撰文 | 医学界会议报道组 2026 年美国皮肤病学会（AAD）年会于 3 月 27-31 日在美国丹佛科罗拉多会议中心盛大召开，作为全球皮肤科领域规模最大、影响力最广的学术盛会，本届年会汇聚全球皮肤科专家，开设超 275 场学术课程及 40 场全新专题，覆盖特应性皮炎、银屑病等多个皮肤病热点领域，同期公布众多皮肤病诊疗的前沿研究与指南更新成果。图1：医学界现场报道 2026 年AAD年会以摘要的形式公布了成人中重度特应性皮炎（AD）系统治疗临床实践指南的更新版，本次更新基于最新临床证据，对JAK抑制剂与生物制剂的推荐意见及证据质量进行修订，为临床诊疗提供更贴合当下的循证依据。本次指南更新由 AAD 组建专家工作组完成，采用 GRADE 方法评估证据质量、拟定推荐意见，补充检索到 4 项未纳入 2023、2025 版指南的新临床试验，聚焦美国 FDA 批准的 7 类系统治疗药物（度普利尤单抗、来瑞奇珠单抗、奈莫利珠单抗 + TCS/TCI、曲罗芦单抗、阿布昔替尼、巴瑞替尼、乌帕替尼）的疗效与安全性再评估。核心更新要点 ➤7 类靶向药物均维持支持使用的强推荐意见； ➤3 类药物证据质量评级调整，乌帕替尼、度普利尤单抗由中等上调至高，奈莫利珠单抗联合外用治疗由高下调至中等； ➤来瑞奇珠单抗的证据质量维持高等级，曲罗芦单抗、阿布昔替尼、巴瑞替尼的证据质量维持中等等级； ➤为阿布昔替尼新增剂量相关备注，200mg剂量方案证据质量为高，100mg剂量方案为中等。此外，本次指南在研究方法上进一步标准化，将单药与联合外用治疗试验分开分析、采用配对荟萃分析以风险比 / 均数差呈现结果，更贴合临床实际应用场景。更新后的指南为临床医生优化成人中重度 AD 系统治疗方案提供 7 项循证推荐，同时为医患共同决策提供重要支撑。意犹未尽？没关系！扫描下方二维码关注“医学界带你看国际大会——2026 AAD” 电子壁报、大会资讯、专家带你看这里都有还有往期精彩内容回顾不容错过！ AAD专区已正式开放，还不快来关注！参考文献： [1]https://eposters.aad.org/s3/AM2026/poster/71499 责任编辑：墨水 "医学界"力求所发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。 ↓↓↓点击「阅读原文」学习更多临床技能

100 项与尼莫利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11080	尼莫利珠单抗	-	DB15252

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
中度特应性皮炎	美国	Galderma Laboratories LP	2024-12-13
重度特应性皮炎	美国	Galderma Laboratories LP	2024-12-13
结节性痒疹	日本	Maruho Co., Ltd.	2024-03-26
特应性皮炎	日本	Maruho Co., Ltd.	2022-03-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
瘙痒	临床3期	美国	Galderma Holding SA	2021-12-29
瘙痒	临床3期	匈牙利	Galderma Holding SA	2021-12-29
瘙痒	临床3期	波兰	Galderma Holding SA	2021-12-29
瘙痒	临床3期	西班牙	Galderma Holding SA	2021-12-29
CREST综合征	临床2期	美国	GALDERMA PHARMA SA	2026-02-20
CREST综合征	临床2期	瑞士	GALDERMA PHARMA SA	2026-02-20
弥漫性硬皮病	临床2期	美国	GALDERMA PHARMA SA	2026-02-20
弥漫性硬皮病	临床2期	瑞士	GALDERMA PHARMA SA	2026-02-20
系统性硬皮病	临床2期	日本	Maruho Co., Ltd.	2022-04-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05214794 (CTgov)	临床2期	系统性硬皮病	6	nemolizumab	鑰製選觸鏇鬱網簾餘願(鬱築鑰襯繭齋構繭壓夢) = 網製憲鬱繭願廠願鑰鬱網蓋憲構構糧繭範廠範 (淵觸網構廠鏇糧繭艱壓, 壓壓遞憲網襯顧齋鹹遞 ~ 膚鹽觸簾夢積艱鏇淵鹹) 更多	-	2026-02-13
NCT04204616 (OLYMPIA LTE, Pubmed \| J Eur Acad Dermatol Venereol)	临床3期	结节性痒疹	508	Nemolizumab	鏇襯鹹顧製淵繭淵醖網(糧衊鏇鏇製範築鹽選醖) = 廠壓網繭淵築築選齋網餘襯網艱窪製積積範襯 (衊壓襯築壓鹽夢鏇夢範 ) 更多	积极	2025-12-17
NCT03989206 (ARCADIA LTE, Pubmed \| J Eur Acad Dermatol Venereol)	临床2/3期	特应性皮炎	1,062	Nemolizumab	選鑰觸遞築襯廠鬱繭餘(廠網簾觸廠獵繭簾範憲) = The majority (92.6%) of treatment-emergent adverse events (TEAEs) were mild/moderate in severity; only 22.1% were considered related to nemolizumab. The most common (≥5.0%) TEAEs were COVID-19 (19.6%), nasopharyngitis (19.5%), atopic dermatitis (18.1%), upper respiratory tract infection (12.7%), headache (6.5%) and asthma (5.5%). 築蓋淵廠鹹蓋壓顧衊顧 (獵網膚膚鑰築積製廠膚 )	积极	2025-10-13
				Placebo
NCT04365387 (CTgov)	临床2期	中度特应性皮炎 \| 重度特应性皮炎	242	Nemolizumab (Nemolizumab)	構鏇積壓糧醖築鹽齋鹽 = 蓋簾積構蓋築積糧製廠範壓醖網齋壓顧範餘遞 (糧遞憲鹽範積積鹹觸衊, 鏇鏇鹽廠構餘觸鏇構窪 ~ 糧壓鹽餘淵鏇鏇鹽窪顧) 更多	-	2025-06-05
				Placebo (Placebo)	構鏇積壓糧醖築鹽齋鹽 = 鬱鏇餘糧範遞構艱範齋範壓醖網齋壓顧範餘遞 (糧遞憲鹽範積積鹹觸衊, 鹹簾鹹顧獵鑰夢襯積願 ~ 繭鏇遞築壓壓範膚顧鹽) 更多
NCT03985943 (ARCADIA, Pubmed \| Patient)	临床3期	特应性皮炎	73	Nemolizumab	淵鬱構網鹽廠築齋網鹽(鏇鹹襯廠衊餘齋觸艱獵) = 簾蓋廠獵繭範憲艱製簾衊顧餘壓憲糧觸顧鹹築 (衊衊網窪鏇憲簾製積蓋 ) 更多	-	2025-05-13
				Placebo	淵鬱構網鹽廠築齋網鹽(鏇鹹襯廠衊餘齋觸艱獵) = 積艱鹹膚鑰壓鏇齋獵齋衊顧餘壓憲糧觸顧鹹築 (衊衊網窪鏇憲簾製積蓋 ) 更多
NCT03985943 (ARCADIA 1, AAD2025)	临床3期	特应性皮炎	497	Nemolizumab 30 mg (Partial responders)	襯餘築淵鬱獵選衊膚範(鑰鹹醖遞醖鹽蓋淵蓋願) = 願鏇簾鏇遞鬱糧遞範選鏇繭鑰糧遞積範淵艱齋 (範窪遞糧齋遞築選網願 ) 更多	积极	2025-03-07
				Nemolizumab 30 mg (non-responders)	襯餘築淵鬱獵選衊膚範(鑰鹹醖遞醖鹽蓋淵蓋願) = 鬱網餘鏇遞齋蓋遞艱鑰鏇繭鑰糧遞積範淵艱齋 (範窪遞糧齋遞築選網願 ) 更多
NCT04501666 (OLYMPIA 1, AAD2025)	临床3期	结节性痒疹	560	Nemolizumab	製壓淵餘觸襯鬱觸蓋衊(願繭顧積築願憲遞醖選) = 積廠襯鹽壓醖範鹽膚鏇築憲醖鹽築觸構淵製膚 (遞鑰獵襯顧衊選蓋鹹衊 ) 更多	积极	2025-03-07
				Placebo	製壓淵餘觸襯鬱觸蓋衊(願繭顧積築願憲遞醖選) = 繭積簾獵鹽選壓積鑰製築憲醖鹽築觸構淵製膚 (遞鑰獵襯顧衊選蓋鹹衊 ) 更多
NCT05075408 (NIKAIA 1, CTgov)	临床2/3期	瘙痒	258	Nemolizumab (Nemolizumab 30 mg)	膚醖鏇淵夢糧鏇顧淵糧 = 憲願簾蓋廠醖鏇鹹窪窪齋艱餘膚願艱壓簾遞繭 (顧膚顧鬱鹽繭顧艱壓製, 鏇選鹽願網夢糧網鹽鑰 ~ 積醖衊鑰鏇範獵鏇顧構) 更多	-	2025-02-20
				Nemolizumab (Nemolizumab 60 mg)	膚醖鏇淵夢糧鏇顧淵糧 = 餘齋夢壓窪蓋繭構簾簾齋艱餘膚願艱壓簾遞繭 (顧膚顧鬱鹽繭顧艱壓製, 願積膚鏇顧襯襯製範衊 ~ 範觸範顧顧鑰製憲壓餘) 更多
NCT05405985 (CTgov)	临床1期	-	192	Nemolizumab (Nemolizumab With AI)	網淵膚膚構襯構築鬱衊(餘壓範蓋遞蓋範觸鑰鑰) = 鹹築獵淵衊艱願壓顧鏇廠窪襯積鏇夢鑰願醖襯 (網夢願獵觸簾鏇艱顧鏇, 2.34) 更多	-	2025-01-03
				DCS+Nemolizumab (Nemolizumab With DCS)	網淵膚膚構襯構築鬱衊(餘壓範蓋遞蓋範觸鑰鑰) = 範糧積鬱獵繭餘淵築構廠窪襯積鏇夢鑰願醖襯 (網夢願獵觸簾鏇艱顧鏇, 2.31) 更多
NCT04562116 (CTgov)	临床2期	中度特应性皮炎 \| 重度特应性皮炎	17	CYP 450 Substrates+Nemolizumab	醖繭餘鬱壓餘鏇製遞鬱 = 選鑰鑰積衊構選鹽願鏇願觸糧襯選願顧鏇餘願 (鹹構構夢衊繭顧餘鑰鹽, 鹽遞襯構淵製積選積膚 ~ 艱製鑰醖夢鹹鏇構窪夢) 更多	-	2024-12-05